^
    Back
    Association details:
    Biomarker:ER Y537N
    Cancer:Ovarian Serous Adenocarcinoma
    Drug:fulvestrant (Selective estrogen receptor degrader)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    ASCO 2018
    Title:

    Assessment of activating estrogen receptor 1 (ESR1) mutations in gynecologic malignancies.

    Published date:
    05/16/2018
    Excerpt:
    LGSOC patient had a mutESR1 Y537N at diagnosis and has attained prolonged clinical benefit ( > 4 years) with fulvestrant.
    DOI:
    10.1200/JCO.2018.36.15_suppl.5590